Safety and efficacy of transition from inhaled treprostinil to parenteral treprostinil in selected patients with pulmonary arterial hypertension

Ioana R. Preston, Jeremy Feldman, James White, Veronica Franco, David Ishizawar, Charles Dwayne Burger, Aaron B. Waxman, Nicholas S. Hill

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Guidelines for the treatment of pulmonary arterial hypertension (PAH) recommend sequential add-on therapy for patients who deteriorate or fail to improve clinically. However, it is not known whether these patients also benefit from transitioning from inhaled prostacyclins to parenteral prostacyclins. We sought to characterize PAH patients receiving inhaled treprostinil who were transitioned to parenteral tre-prostinil. We conducted a multicenter retrospective study at 7 PAH centers and collected reasons, methods, safety, and outcome of patients transitioned from inhaled treprostinil to parenteral treprostinil. Twenty-six patients with pulmonary hypertension in group 1, 4, or 5 transitioned from inhaled treprostinil to parenteral treprostinil (10 intravenous, 16 subcutaneous). Twenty-four patients were also on one or two oral therapies. Reasons for transition were clinical deterioration, lack of clinical improvement, and pregnancy (19, 6, and 1 patients, respectively). Transitions occurred in hospital, clinic, or home (17, 7, and 2 patients, respectively). Parenteral infusion was started after the last inhaled treatment at maintenance dose (13 patients), after the inhaled therapy was downtitrated to 18µg (6 patients), or with an overlap of inhaled downtitration with parenteral uptitration (7 patients). The transition was safe; side effects included symptoms of prostacyclin overdose. Patients were followed for 3-18 months. At 3 months, 8 patients improved, 17 maintained their functional class, and 1 continued to deteriorate. In conclusion, selected PAH patients can be safely transitioned from inhaled treprostinil to parenteral treprostinil using a variety of methodologies in different settings with the expectation that patients will improve or at least remain clinically stable.

Original languageEnglish (US)
Pages (from-to)456-461
Number of pages6
JournalPulmonary Circulation
Volume4
Issue number3
DOIs
StatePublished - Sep 1 2014

Fingerprint

Pulmonary Hypertension
Safety
Prostaglandins I
treprostinil
Parenteral Infusions
Therapeutics
Epoprostenol
Patient Safety
Multicenter Studies
Retrospective Studies
Guidelines

Keywords

  • Goal-oriented therapy
  • Multicenter study
  • Prostacyclin analogues

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Safety and efficacy of transition from inhaled treprostinil to parenteral treprostinil in selected patients with pulmonary arterial hypertension. / Preston, Ioana R.; Feldman, Jeremy; White, James; Franco, Veronica; Ishizawar, David; Burger, Charles Dwayne; Waxman, Aaron B.; Hill, Nicholas S.

In: Pulmonary Circulation, Vol. 4, No. 3, 01.09.2014, p. 456-461.

Research output: Contribution to journalArticle

Preston, Ioana R. ; Feldman, Jeremy ; White, James ; Franco, Veronica ; Ishizawar, David ; Burger, Charles Dwayne ; Waxman, Aaron B. ; Hill, Nicholas S. / Safety and efficacy of transition from inhaled treprostinil to parenteral treprostinil in selected patients with pulmonary arterial hypertension. In: Pulmonary Circulation. 2014 ; Vol. 4, No. 3. pp. 456-461.
@article{ed4a5e9cd5d544a5922a781ce1818b53,
title = "Safety and efficacy of transition from inhaled treprostinil to parenteral treprostinil in selected patients with pulmonary arterial hypertension",
abstract = "Guidelines for the treatment of pulmonary arterial hypertension (PAH) recommend sequential add-on therapy for patients who deteriorate or fail to improve clinically. However, it is not known whether these patients also benefit from transitioning from inhaled prostacyclins to parenteral prostacyclins. We sought to characterize PAH patients receiving inhaled treprostinil who were transitioned to parenteral tre-prostinil. We conducted a multicenter retrospective study at 7 PAH centers and collected reasons, methods, safety, and outcome of patients transitioned from inhaled treprostinil to parenteral treprostinil. Twenty-six patients with pulmonary hypertension in group 1, 4, or 5 transitioned from inhaled treprostinil to parenteral treprostinil (10 intravenous, 16 subcutaneous). Twenty-four patients were also on one or two oral therapies. Reasons for transition were clinical deterioration, lack of clinical improvement, and pregnancy (19, 6, and 1 patients, respectively). Transitions occurred in hospital, clinic, or home (17, 7, and 2 patients, respectively). Parenteral infusion was started after the last inhaled treatment at maintenance dose (13 patients), after the inhaled therapy was downtitrated to 18µg (6 patients), or with an overlap of inhaled downtitration with parenteral uptitration (7 patients). The transition was safe; side effects included symptoms of prostacyclin overdose. Patients were followed for 3-18 months. At 3 months, 8 patients improved, 17 maintained their functional class, and 1 continued to deteriorate. In conclusion, selected PAH patients can be safely transitioned from inhaled treprostinil to parenteral treprostinil using a variety of methodologies in different settings with the expectation that patients will improve or at least remain clinically stable.",
keywords = "Goal-oriented therapy, Multicenter study, Prostacyclin analogues",
author = "Preston, {Ioana R.} and Jeremy Feldman and James White and Veronica Franco and David Ishizawar and Burger, {Charles Dwayne} and Waxman, {Aaron B.} and Hill, {Nicholas S.}",
year = "2014",
month = "9",
day = "1",
doi = "10.1086/677360",
language = "English (US)",
volume = "4",
pages = "456--461",
journal = "Pulmonary Circulation",
issn = "2045-8932",
publisher = "University of Chicago Press",
number = "3",

}

TY - JOUR

T1 - Safety and efficacy of transition from inhaled treprostinil to parenteral treprostinil in selected patients with pulmonary arterial hypertension

AU - Preston, Ioana R.

AU - Feldman, Jeremy

AU - White, James

AU - Franco, Veronica

AU - Ishizawar, David

AU - Burger, Charles Dwayne

AU - Waxman, Aaron B.

AU - Hill, Nicholas S.

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Guidelines for the treatment of pulmonary arterial hypertension (PAH) recommend sequential add-on therapy for patients who deteriorate or fail to improve clinically. However, it is not known whether these patients also benefit from transitioning from inhaled prostacyclins to parenteral prostacyclins. We sought to characterize PAH patients receiving inhaled treprostinil who were transitioned to parenteral tre-prostinil. We conducted a multicenter retrospective study at 7 PAH centers and collected reasons, methods, safety, and outcome of patients transitioned from inhaled treprostinil to parenteral treprostinil. Twenty-six patients with pulmonary hypertension in group 1, 4, or 5 transitioned from inhaled treprostinil to parenteral treprostinil (10 intravenous, 16 subcutaneous). Twenty-four patients were also on one or two oral therapies. Reasons for transition were clinical deterioration, lack of clinical improvement, and pregnancy (19, 6, and 1 patients, respectively). Transitions occurred in hospital, clinic, or home (17, 7, and 2 patients, respectively). Parenteral infusion was started after the last inhaled treatment at maintenance dose (13 patients), after the inhaled therapy was downtitrated to 18µg (6 patients), or with an overlap of inhaled downtitration with parenteral uptitration (7 patients). The transition was safe; side effects included symptoms of prostacyclin overdose. Patients were followed for 3-18 months. At 3 months, 8 patients improved, 17 maintained their functional class, and 1 continued to deteriorate. In conclusion, selected PAH patients can be safely transitioned from inhaled treprostinil to parenteral treprostinil using a variety of methodologies in different settings with the expectation that patients will improve or at least remain clinically stable.

AB - Guidelines for the treatment of pulmonary arterial hypertension (PAH) recommend sequential add-on therapy for patients who deteriorate or fail to improve clinically. However, it is not known whether these patients also benefit from transitioning from inhaled prostacyclins to parenteral prostacyclins. We sought to characterize PAH patients receiving inhaled treprostinil who were transitioned to parenteral tre-prostinil. We conducted a multicenter retrospective study at 7 PAH centers and collected reasons, methods, safety, and outcome of patients transitioned from inhaled treprostinil to parenteral treprostinil. Twenty-six patients with pulmonary hypertension in group 1, 4, or 5 transitioned from inhaled treprostinil to parenteral treprostinil (10 intravenous, 16 subcutaneous). Twenty-four patients were also on one or two oral therapies. Reasons for transition were clinical deterioration, lack of clinical improvement, and pregnancy (19, 6, and 1 patients, respectively). Transitions occurred in hospital, clinic, or home (17, 7, and 2 patients, respectively). Parenteral infusion was started after the last inhaled treatment at maintenance dose (13 patients), after the inhaled therapy was downtitrated to 18µg (6 patients), or with an overlap of inhaled downtitration with parenteral uptitration (7 patients). The transition was safe; side effects included symptoms of prostacyclin overdose. Patients were followed for 3-18 months. At 3 months, 8 patients improved, 17 maintained their functional class, and 1 continued to deteriorate. In conclusion, selected PAH patients can be safely transitioned from inhaled treprostinil to parenteral treprostinil using a variety of methodologies in different settings with the expectation that patients will improve or at least remain clinically stable.

KW - Goal-oriented therapy

KW - Multicenter study

KW - Prostacyclin analogues

UR - http://www.scopus.com/inward/record.url?scp=85026337196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026337196&partnerID=8YFLogxK

U2 - 10.1086/677360

DO - 10.1086/677360

M3 - Article

AN - SCOPUS:85026337196

VL - 4

SP - 456

EP - 461

JO - Pulmonary Circulation

JF - Pulmonary Circulation

SN - 2045-8932

IS - 3

ER -